{"DataElement":{"publicId":"5918302","version":"1","preferredName":"Kaposi Sarcoma Lesion Critera Assessment","preferredDefinition":"The response assessment of the final result of a determination of the value, significance, or extent of Kaposi Sarcoma lesions.","longName":"KS_LES_ASSES","context":"CITN","contextVersion":"1","DataElementConcept":{"publicId":"5917699","version":"1","preferredName":"Kaposi Sarcoma Lesion Assessment","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS)._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._The final result of a determination of the value, significance, or extent of.","longName":"2639367v1.0:5917697v1.0","context":"CITN","contextVersion":"1","ObjectClass":{"publicId":"2639367","version":"1","preferredName":"Kaposi Sarcoma","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","longName":"C9087","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"30BF3151-5EE1-1E4A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-18","modifiedBy":"ONEDATA","dateModified":"2007-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2674665","version":"1","preferredName":"Lesion Assessment","preferredDefinition":"(LEE-zhun) An area of abnormal tissue change.:The final result of a determination of the value, significance, or extent of.","longName":"C3824:C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"385E1A0D-752C-038B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-08-23","modifiedBy":"ONEDATA","dateModified":"2007-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55DF8B68-978B-638D-E053-F662850A7048","latestVersionIndicator":"Yes","beginDate":"2017-08-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-03","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeDescription":"8/3/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5918293","version":"1","preferredName":"Kaposi Sarcoma Type","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS)._._Something distinguishable as an identifiable class based on common qualities.","longName":"5918293v1.0","context":"CITN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Greater than or Equal to 50% decrease # Nodular Lesions","valueDescription":"Greater than or Equal to 50% decrease # Nodular Lesions","ValueMeaning":{"publicId":"5918294","version":"1","preferredName":"Greater than or Equal to 50% decrease # Nodular Lesions","longName":"5918294","preferredDefinition":"Greater than or Equal to 50% decrease # Nodular Lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BA8E2-2FAF-2087-E053-F662850AEE5E","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562BA8E2-2FC8-2087-E053-F662850AEE5E","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"},{"value":"Greater than or Equal to 50% decrease # Total Lesions","valueDescription":"Greater than or Equal to 50% decrease # Total Lesions","ValueMeaning":{"publicId":"5918295","version":"1","preferredName":"Greater than or Equal to 50% decrease # Total Lesions","longName":"5918295","preferredDefinition":"Greater than or Equal to 50% decrease # Total Lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BA8E2-2FD2-2087-E053-F662850AEE5E","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562BA8E2-2FEB-2087-E053-F662850AEE5E","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"},{"value":"Greater than or Equal to 50% decrease area of measured lesions","valueDescription":"Greater than or Equal to 50% decrease area of measured lesions","ValueMeaning":{"publicId":"5918296","version":"1","preferredName":"Greater than or Equal to 50% decrease area of measured lesions","longName":"5918296","preferredDefinition":"Greater than or Equal to 50% decrease area of measured lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BA8E2-2FF5-2087-E053-F662850AEE5E","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562BA8E2-300E-2087-E053-F662850AEE5E","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"},{"value":"Greater than or Equal to 50% decrease measurable visceral lesions complete disappearance of non-measurable lesions","valueDescription":"Greater than or Equal to 50% decrease measurable visceral lesions complete disappearance of non-measurable lesions","ValueMeaning":{"publicId":"5918297","version":"1","preferredName":"Greater than or Equal to 50% decrease measurable visceral lesions complete disappearance of non-measurable lesions","longName":"5918297","preferredDefinition":"Greater than or Equal to 50% decrease measurable visceral lesions complete disappearance of non-measurable lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BA8E2-3018-2087-E053-F662850AEE5E","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562BA8E2-3031-2087-E053-F662850AEE5E","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"},{"value":"Greater than or Equal to 25% increase # Nodular Lesions","valueDescription":"Greater than or Equal to 25% increase # Nodular Lesions","ValueMeaning":{"publicId":"5918298","version":"1","preferredName":"Greater than or Equal to 25% increase # Nodular Lesions","longName":"5918298","preferredDefinition":"Greater than or Equal to 25% increase # Nodular Lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BA8E2-303B-2087-E053-F662850AEE5E","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562BA8E2-3054-2087-E053-F662850AEE5E","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"},{"value":"Greater than or Equal to 25% increase # Total Lesions","valueDescription":"Greater than or Equal to 25% increase # Total Lesions","ValueMeaning":{"publicId":"5918299","version":"1","preferredName":"Greater than or Equal to 25% increase # Total Lesions","longName":"5918299","preferredDefinition":"Greater than or Equal to 25% increase # Total Lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BA8E2-305E-2087-E053-F662850AEE5E","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562BA8E2-3077-2087-E053-F662850AEE5E","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"},{"value":"Greater than or Equal to 25% increase area of measured lesions","valueDescription":"Greater than or Equal to 25% increase area of measured lesions","ValueMeaning":{"publicId":"5918300","version":"1","preferredName":"Greater than or Equal to 25% increase area of measured lesions","longName":"5918300","preferredDefinition":"Greater than or Equal to 25% increase area of measured lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BA8E2-3081-2087-E053-F662850AEE5E","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562BA8E2-309A-2087-E053-F662850AEE5E","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"},{"value":"Unequivocal worsening of non-measurable lesions","valueDescription":"Unequivocal worsening of non-measurable lesions","ValueMeaning":{"publicId":"5918318","version":"1","preferredName":"Unequivocal worsening of non-measurable lesions","longName":"5918318","preferredDefinition":"Unequivocal worsening of non-measurable lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562EE5B7-5675-6557-E053-F662850AD4A8","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562EE5B7-568E-6557-E053-F662850AD4A8","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"},{"value":"Greater than or Equal to 25% increase measurable visceral lesions","valueDescription":"Greater than or Equal to 25% increase measurable visceral lesions","ValueMeaning":{"publicId":"5918319","version":"1","preferredName":"Greater than or Equal to 25% increase measurable visceral lesions","longName":"5918319","preferredDefinition":"Greater than or Equal to 25% increase measurable visceral lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562EF41B-6834-768F-E053-F662850A5334","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"562EF41B-684D-768F-E053-F662850A5334","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5918303","version":"1","preferredName":"Kaposi Sarcoma Type","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).:Something distinguishable as an identifiable class based on common qualities.","longName":"C9087:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562D6E83-99D3-0DDD-E053-F662850A23E9","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"ONEDATA","dateModified":"2017-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BA8E2-2F9A-2087-E053-F662850AEE5E","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"CITN - 1","type":"Alternate Question Text","description":"If PD, Criteria for PD","url":null,"context":"CITN"},{"name":"If PR, Criteria for PR","type":"Preferred Question Text","description":"If PR, Criteria for PR","url":null,"context":"CITN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BAB20-9C9F-3679-E053-F662850A5175","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeDescription":"8/7/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}